ClinicalTrials.gg
CompletedNCT04163783Updated Nov 15, 2019

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males

A Phase 1 interventional study of [14C]-BGB-3111 and BGB-3111 in Healthy Volunteers, sponsored by BeiGene. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-15.

Sponsored by BeiGene · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Apr 2017, 9 years 6 months ago, and no results have been posted to the registry.
  • Registered 2 years 7 months after the study started (first participant enrolled Mar 2017, registered Nov 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Phase 1 study in healthy subjects to determine the effect of an 8-hour fast from food on the pharmacokinetics of [14C]-BGB-3111.

Read the detailed description

This study will be an open-label, non-randomized study to evaluate the pharmacokinetics of [14C]-BGB-3111 when administered in healthy male subjects following at least an 8-hour fast from food (not including water).

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Phase 1
  • Pharmacokinetics
  • Safety
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male between 18 and 65 years of age, inclusive, at Screening
  2. between 18.0 and 35.0 kg/m2, inclusive, at Screening
  3. In good health, determined by no findings from medical history,12-lead ECGs, or vital signs measurements
  4. Clinical laboratory evaluations

Exclusion criteria

Exclusion Criteria:

  1. Significant history or clinical manifestation of any metabolic, allergic, infectious, dermatological, hepatic, renal, hematological, pulmonary, metabolic, cardiovascular, gastrointestinal, neurological, or psychiatric disorder (as determined by the Investigator [or designee]) prior to Check-in
  2. History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) prior to Check-in
  3. History of stomach or intestinal surgery or resection that could alter absorption or excretion of orally administered drugs prior to Check-in except that appendectomy and hernia repair will be allowed if it was not associated with complications
  4. Abnormal liver function tests
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Arm A

    Subjects will be administered a single oral dose of 320 mg of \[14C\]-BGB-3111

    Drug: [14C]-BGB-3111 · Drug: BGB-3111

Interventions

  • 20-mg capsule containing \~200 μCi of \[14C\]-BGB-3111,

  • Three 20-mg capsules of BGB-3111 and three 80-mg capsules of BGB-3111

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Parameter: Plasma concentration of [14C]-BGB-3111 as measured by area under concentration-time curve (AUC)

    Time frame: Up to 13 days

  2. Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) of [14C]-BGB-3111

    Time frame: Up to 13 days

  3. Pharmacokinetic Parameter: Time To Maximum Plasma Concentration (Tmax) of [14C]-BGB-3111

    Time frame: Up to 13 days

  4. Pharmacokinetic Parameter: apparent terminal elimination rate constant (λZ) of [14C]-BGB-3111

    Time frame: Up to 13 days

  5. Pharmacokinetic Parameter: Half-life Period of (T1/2) of [14C]-BGB-3111

    Time frame: Up to 13 days

  6. Pharmacokinetic Parameter: apparent systemic clearance (CL/F) of [14C]-BGB-3111

    Time frame: Up to 13 days

  7. Pharmacokinetic Parameter: apparent volume of distribution during the terminal phase (Vz/F) of [14C]-BGB-3111

    Time frame: Up to 13 days

  8. Blood and plasma concentrations of total radioactivity: Maximum Plasma Concentration (Cmax) of [14C]-BGB-3111

    Time frame: Up to 13 days

  9. Blood and plasma concentrations of total radioactivity: Time To Maximum Plasma Concentration (Tmax) of [14C]-BGB-3111

    Time frame: Up to 13 days

  10. Blood and plasma concentrations of total radioactivity of [14C]-BGB-3111 as measured by area under concentration-time curve (AUC)

    Time frame: Up to 13 days

  11. Blood and plasma concentrations of total radioactivity: apparent terminal elimination rate constant (λZ) of [14C]-BGB-3111

    Time frame: Up to 13 days

  12. Blood and plasma concentrations of total radioactivity: Half-life Period of (T1/2) of [14C]-BGB-3111

    Time frame: Up to 13 days

  13. Blood and plasma concentrations of total radioactivity: apparent systemic clearance (CL/F) of [14C]-BGB-3111

    Time frame: Up to 13 days

  14. Blood and plasma concentrations of total radioactivity: apparent volume of distribution during the terminal phase (Vz/F) of [14C]-BGB-3111

    Time frame: Up to 13 days

  15. Urinary recovery of total radioactivity of [14C]-BGB-3111 as assessed by the amount excreted in urine per sampling interval (Aeu)

    Time frame: Up to 13 days

  16. Urinary recovery of total radioactivity of [14C]-BGB-3111 as assessed by the cumulative amount excreted in urine per sampling interval (Cum Aeu)

    Time frame: Up to 13 days

  17. Urinary recovery of total radioactivity of [14C]-BGB-3111 as assessed by the percentage of drug or radioactive dose excreted in urine per sampling interval (%Feu)

    Time frame: Up to 13 days

  18. Urinary recovery of total radioactivity of [14C]-BGB-3111 as assessed by the cumulative percentage of drug or radioactive dose excreted in urine (Cum %Feu)

    Time frame: Up to 13 days

  19. Urinary recovery of total radioactivity as assessed by the renal clearance (CLR; for BGB-3111 only)

    Time frame: Up to 13 days

  20. Fecal recovery of total radioactivity as assessed by the amount of [14C]-BGB-3111 excreted in feces per sampling interval (Aef)

    Time frame: Up to 13 days

  21. Fecal recovery of total radioactivity as assessed by the cumulative amount of [14C]-BGB-3111 excreted in feces per sampling interval (Cum Aef)

    Time frame: Up to 13 days

  22. Fecal recovery of total radioactivity as assessed by the percentage of radioactive dose excreted in feces per sampling interval (%Fef)

    Time frame: Up to 13 days

  23. Fecal recovery of total radioactivity as assessed by the cumulative percentage of radioactive dose excreted in feces per sampling interval (Cum %Fef)

    Time frame: Up to 13 days

  24. Mass balance

    Urine and fecal collection for Mass Balance Evaluation

    Time frame: Up to 13 days

  25. Routes of elimination of [14C]-BGB-3111

    Urine and fecal collection for Metabolite Profiling/Characterization

    Time frame: Up to 13 days

Secondary outcomes

  1. Characterize and identify metabolites of [14C]-BGB-3111

    plasma, urine, and feces collection

    Time frame: Up to 13 days

  2. plasma and urine concentrations of BGB-3111

    plasma and urine collection

    Time frame: up to 13 days

  3. Number of Participants experiencing Adverse events (AEs)

    Time frame: up to 13 days

  4. Number of Participants experiencing abnormal clinical laboratory evaluations

    Time frame: up to 13 days

07

Study locations

1 site
  • Covance Clinical Research Unit, Inc.,
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Apr 2017, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2019
First posted
Nov 15, 2019
StartActual
Mar 29, 2017
Primary completionActual
Apr 18, 2017
CompletionActual
Apr 18, 2017
Last update
Nov 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04163783
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Nov 15, 2019
Start date
Mar 29, 2017
Primary completion
Apr 18, 2017
Completion
Apr 18, 2017
Last update
Nov 15, 2019

Study contacts

William Novotony, MD
study director · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion